Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2009
04/21/2009US7521570 Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof
04/21/2009US7521569 Process to obtain dibenzylbutyrolactonic lignans, process to obtain synthetic derivatives from lignans bearing anti-Chagas chemoprophylactic and therapeutical activities
04/21/2009US7521563 Hydroxamic acid derivative and medicine containing the same as active ingredient
04/21/2009US7521561 Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma
04/21/2009US7521553 Crystalline forms of lamotrigine
04/21/2009US7521481 administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation
04/21/2009US7521480 Such as 2-[3-(3-Bromo-phenyl)-ureido]-4-chloro-5-methyl-benzenesulfonic acid which is selective and non-competitive antagonist of ionotropic GluR5 receptor
04/21/2009US7521479 Administering chaotropic agent
04/21/2009US7521478 Antitumor agents; synthetic derivatives equivalent to marine polyketide derived components isolated from bryozoan Myriapora truncata; removing protecting groups from intermediates
04/21/2009US7521477 Vitamin C derivatives with peptide, preparation method thereof and composition comprising the same
04/21/2009US7521476 Aminoacetonitrile derivatives suitable for controlling parasites
04/21/2009US7521475 Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof
04/21/2009US7521474 For blocking cellular proliferation, treatment of cancer/fungal infections, controlling spoilage of food, and in cosmetics
04/21/2009US7521473 Inhibitors of protein tyrosine phosphatase 1B
04/21/2009US7521472 Crystal of two-ring heterocyclic sulfonamide compound
04/21/2009US7521471 CB1cannabinoid receptor antagonists; e.g. 5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-1H-pyrazole-3-carboxamide; various psychological, neurodegenerative, pain and cardiovascular disorders
04/21/2009US7521470 Factor Xa inhibitors
04/21/2009US7521469 E.g., (5R,8R,11S)-5-benzyl-6-hydroxy-11-(1H-indol-3-ylmethyl)-3,9-dioxo-1-phenyl-8-[(3-phenyl-5-isoxazolyl)methyl]-2-oxa-4,10-diaza-6-phosphadodecan-12-oic Acid 6-oxide; simultaneously inhibit angiotensin converting enzyme and endothelin converting enzyme; treatment of arterial hypertension
04/21/2009US7521468 Administering phenolic derivatives including 6-methoxy-2,3-benzoxazolinone (6-MBOA), benzoxazinoids-cyclic hydroxyamic acids, lactams, and corresponding glucosides; antiarthritic, antidiabetic, and hypoglycemic agents; sleep disorders, fibromyalgia; monocotyledon plant extracts
04/21/2009US7521467 Administering phenolic derivatives including 6-methoxy-2,3-benzoxazolinone (6-MBOA), benzoxazinoids-cyclic hydroxyamic acids, lactams, and corresponding glucosides; antiarthritic, antidiabetic, and hypoglycemic agents; sleep disorders, fibromyalgia; monocotyledon plant extracts
04/21/2009US7521465 thiazolidin-2,4-diones or -oxazolidin-2,4-diones or thiones; obesity, inflammation, autoimmune diseases (multiple sclerosis, rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic.
04/21/2009US7521464 drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome
04/21/2009US7521463 Immunomodulatory compounds
04/21/2009US7521462 4-Amino-piperidine derivatives as monoamine uptake inhibitors
04/21/2009US7521461 2-{[4-(2-Oxo-2-{[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]methyl}benzoic acid; peroxisome proliferator activated receptors alpha and gamma agonist; antidiabetic agents; Insulin Resistance Syndrome (IRS); cardiovascular disorders; myocardial infarction; stroke; atherosclerosis; dyslipidemia
04/21/2009US7521460 e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor
04/21/2009US7521459 Method for treating damaged skin
04/21/2009US7521458 Spiropiperidylrifamycins for the treatment of mycobacterial infections
04/21/2009US7521457 Pyrimidines as PLK inhibitors
04/21/2009US7521456 Antiproliferative agents; anticancer agents; Erlotinib mesylate
04/21/2009US7521455 Histamine H3 receptor antagonist or inverse agonist activity; metabolic diseases, circulatory diseases, or nervous system diseases; e.g. 3-(4-((1-cyclobutyl-4-piperidinyl)oxy)phenyl)-2-ethylpyrido(2,3-d)pyrimidin-4(3H)-one
04/21/2009US7521454 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis
04/21/2009US7521453 e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer
04/21/2009US7521452 Preparation of pharmaceutical salts of piperazine compounds
04/21/2009US7521451 e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction
04/21/2009US7521450 Inhibitors of kinases
04/21/2009US7521449 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof
04/21/2009US7521448 N-substituted benzimidazolyl c-Kit inhibitors
04/21/2009US7521447 2-aza-[4.3.0]bicyclic heteroaromatic rings; useful for the treatment of inflammation, osteoarthritis, rheumatoid arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, cancer, autoimmune diseases, and for the treatment of other cytokine-mediated diseases
04/21/2009US7521446 4-({8-[(2,6-Difluorophenyl)amino]-9-cyclopentylpurin-2-yl}amino) trans-cyclohexan-1-ol; mitogen-activated protein (tyrosine) kinase inhibitor; anticarcinogenic, antiinflammatory, analgesic agent, cardiovascular disease, renal disease, autoimmune condition, macular degeneration, pulmonary hypertension
04/21/2009US7521445 Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
04/21/2009US7521444 Enzyme inhibitors; interferons; interleukins; cyclosporins
04/21/2009US7521443 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma
04/21/2009US7521442 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
04/21/2009US7521441 8-Cyclohexyl-1,1a,2,12b-tetrahydro-1a-(4-morpholinylcarbonyl)-cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxylic acid, methyl ester; RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma
04/21/2009US7521440 Targeted oxidative therapeutic formulation
04/21/2009US7521439 Glucocorticoid receptor ligands for the treatment of metabolic disorders
04/21/2009US7521438 Allergies,chronic obstructive airway disorders (COPD), e.g. bronchial asthma, chronic obstructive bronchitis, pulmonary emphysema with reversible obstruction, bronchial asthma and other bronchial disorders; side effect reduction
04/21/2009US7521437 7-phenyl-substituted tetracycline compounds
04/21/2009US7521436 Modified phosphocalcic compound, injectable composition containing same
04/21/2009US7521435 Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
04/21/2009US7521434 Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making them
04/21/2009US7521433 Complex in which single-stranded nucleic acid is bound to a double-stranded beta -1,3-glucan which as 1,6-glucopyranoside branch and is chemically modified through periodate oxidation and reductive amination so as to impart nucleic acid-binding functional groups; for use as an antisense agent
04/21/2009US7521432 Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
04/21/2009US7521431 Compositions and methods for siRNA inhibition of HIF-1 alpha
04/21/2009US7521430 N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter
04/21/2009US7521429 each case in free form or in salt form; pesticidal compositions in which the active ingredient has been selected from those compounds and their tautomers; and a method of controlling pests using those compositions are described.** Image-1
04/21/2009US7521428 2',4'',13-Tri-O-benzoyl-8,9-Anhydro-pseudoerythromycin A 6,9-hemiketal; 2'-O-acetyl-4''-O-benzenesulfonyl-12,13-epoxy-8,9-Anhydro-pseudoerythromycin A 6,9-hemiketal; 3'-de-N-methyl-3'-N-{2-amino-(3'-de-N-methyl-erythromycin A)}ethyl-erythromycin A; reducing frequency of appearence of resistant fungus
04/21/2009US7521418 When used in combination with glycopeptide antibacterial agent, the amount of polyene macrolide antifungal agent needed to treat a fungal infection is reduced thereby resulting in fewer side effects
04/21/2009US7521417 Method and apparatus for preparing an acellular red blood cell substitute
04/21/2009US7521414 Polyene-polyol structure; anticancer agents
04/21/2009US7521240 Chromosome-based platforms
04/21/2009US7521239 Method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the
04/21/2009US7521215 Polynucleotides, expression vectors, and host cells for culturing truncated tryptophanyl-tRNA synthetase polypeptides having chemokine activity; bioassay; drug screening; antitumor agents, antimetastasis agents
04/21/2009US7521212 Method for producing oligopolysaccharides
04/21/2009US7521206 Tumor necrosis factor (TNF); immunotherapy or diagnosis of TNF-related diseases such as cancer; nucleic acids, host cells, vectors
04/21/2009US7521191 siRNA targeting connexin 43
04/21/2009US7521177 Contacting the sample with a flavivirus antigen,produced by expressing a transcriptional unit encoding a Japanese encephalitis virus (JEV) signal sequence and an immunogenic flavivirus antigen of a flavivirus; detecting an increase in antigen/antibody complex formation
04/21/2009US7521175 Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
04/21/2009US7521072 Tablet form which is palatable; soluble, which do not significantly increase in viscosity or gel when exposed to water or other liquids, yet possess the desirable organoleptic characteristics
04/21/2009US7521068 For pulmonary and nasal drug administration
04/21/2009US7521066 Administering non-gas containing nanoparticles comprising a mixture of select lipids capable of being internalized within a targeted tissue or cell sufficient to achieve a desired effect and anticancer agent
04/21/2009US7521065 Compositions for the treatment and prevention of cancer
04/21/2009US7521064 Insertion into vagina; prevention, therapy for infections
04/21/2009US7521062 Thiosemicarbazones as anti-virals and immunopotentiators
04/21/2009US7521052 Administering an effective amount of an anti-IL-6 receptor antibody (anti-IL-6R antibody) and an effective amount of methotrexate (MTX) for therapy of rheumatoid arthritis
04/21/2009US7521042 Antihistamines, bronchodilator agents, antiinflammatory agents; mixture of drug and propellant
04/21/2009US7521041 Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction
04/21/2009CA2532330C Highly selective norepinephrine reuptake inhibitors and methods of using the same
04/21/2009CA2499329C Indole-3-carboxamides as glucokinase (gk) activators
04/21/2009CA2400317C Improved paste formulations
04/21/2009CA2384585C Hydrogels for orthopedic repair
04/21/2009CA2377609C Programming ovulation
04/21/2009CA2362003C Heterocyclic urea and related compounds useful as anti-inflammatory agents
04/21/2009CA2356263C Aminopyrazole derivatives
04/21/2009CA2341050C Nucleic acid sequence for potentiating the expression of useful gene and method therefor
04/21/2009CA2339147C Stabilized preparations of .beta.-lactam antibiotic
04/21/2009CA2338358C Compounds and compositions for delivering active agents
04/21/2009CA2336902C Topical compositions comprising an opioid analgesic and an nmda antagonist
04/21/2009CA2320878C Morphine sulphate microgranules, method for making same and pharmaceutical preparations
04/21/2009CA2309038C Use of inhaled no as anti-inflammatory agent
04/21/2009CA2299420C Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
04/21/2009CA2279184C Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
04/21/2009CA2260022C Diagnosis of williams syndrome and williams syndrome cognitive profile by analysis of a lim-kinase gene
04/21/2009CA2231603C Chicken interleukin-15 and uses thereof
04/21/2009CA2228038C 2(1h)-quinolone derivatives, their preparation and their use in therapy
04/21/2009CA2225761C Difluoroprostaglandin derivatives and their use
04/21/2009CA2221341C Submicron liposome suspensions obtained from preliposome lyophilizates
04/21/2009CA2182949C Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
04/21/2009CA2157855C Benzoylguanidines substituted by heterocyclic n-oxide, process for their preparation, their use as a medicament or diagnostic agent, medicament containing them and intermediate products for their preparation